MBRX stock forecast
Our latest prediction for Moleculin Biotech Inc's stock price was made on the Nov. 30, 2022 when the stock price was at 1.44$.
In the short term (2weeks), MBRX's stock price should underperform the market by -3.41%. During that period the price should oscillate between -13.79% and +8.68%.
In the medium term (3months), MBRX's stock price should outperform the market by 2.62%. During that period the price should oscillate between -29.06% and +40.17%.Get email alerts
Create a solid portfolio with MBRX
About Moleculin Biotech Inc
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a NextGeneration Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of None$ per share.
The book value per share is 0.62$
Three months stock forecastNov. 30, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|